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CONCLUSION: Influenza is not a benign disease. For
some infected patients, ER or hospital care is needed.
More aggressive and effective prevention and treatment
strategies may lead to cost avoidance via fewer influenza
related ER visits and hospitalizations.
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COST-EFFECTIVENESS OF ONCE-DAILY 
CLARITHROMYCIN COMPARED TO 
AMOXYCILLIN/CLAVULANIC ACID IN THE 
TREATMENT OF ACUTE EXACERBATION OF 
CHRONIC BRONCHITIS
Hutton J1, Ryan J2, Conway D2
1MEDTAP International, London, UK; 2Abbott Laboratories, 
Abbott Park, IL, USA
OBJECTIVE: Treatment for acute exacerbation of chronic
bronchitis (AECB) frequently consists of antimicrobial
therapy. The persistence of recurrent symptoms can lead
to substantial morbidity and increased healthcare costs.
These factors make it important to consider antimicro-
bial treatment from an economic as well as a clinical per-
spective. This study was designed to assess the relative ef-
fectiveness and cost of once-daily clarithromycin (CL
OD) 500 mg versus amoxycillin/clavulanic acid (AMCL)
625 mg TID in the treatment of AECB. 
METHODS: Of 250 patients enrolled in this investigator-
blind, multicenter, multicountry comparative trial of CL
OD and AMCL in adults with AECB, 127 were random-
ized to treatment with CL OD, and 123 with AMCL. The
primary measure of clinical effectiveness was response to
therapy. Healthcare resource utilization was monitored
from initiation of therapy to 19–23 days after the last study
medication. UK costs were applied to resource use aggre-
gated across all countries in the base case analysis. 
RESULTS: Investigator-defined clinical response rates
were similar in the clinically evaluable population (93/
106 [88%] CL OD and 85/99 [86%] AMCL, p  0.837).
Mean per patient costs were CL OD £120 (95% CI 6–234)
and AMCL £146 (95% CI 5–287). Mean length of stay
for hospitalized patients was 10.80 days for CL OD ver-
sus 15.25 days for AMCL. Both hospitalization costs and
study medication costs were lower for CL OD.
CONCLUSIONS: Previous studies have shown favorable
cost comparisons for CL OD versus AMCL but these
have been based on decision models. Results from this
study provide the first evidence of a trend of cost savings
for CL OD versus AMCL from a prospective random-
ized, multicountry trial.
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SAVINGS IN DIRECT MEDICAL COSTS 
PRODUCED BY AN INHALED SOLUTION OF 
TOBRAMYCIN (TOBI) IN CHILDREN WITH 
CYSTIC FIBROSIS
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OBJECTIVE: Cystic fibrosis is a genetic disease in which
respiratory infections, usually due to Pseudomonas, are
the major cause of morbidity and mortality. A 20-week
double-blind placebo (P) controlled trial conducted in the
United States has shown that a new formulation of To-
bramycin (T) designed for jet nebulization and better tol-
erability produces significant improvements in pulmo-
nary function tests, as well as decreases in the concentra-
tions of Pseudomonas aeruginosa in sputum and a 26%
(95% CI 2–43%) decrease in the probability of being
hospitalized (Ramsey et al. NEJM 340:1;23–30, 1999). 
METHODS: Individual patient-data from the trial were
used to calculate the average number of days spent in
hospital, on home intravenous (IV) and oral antibiotic
therapy. Separate calculations were performed for the
subgroups of patients with FEV1 	50% of predicted and
FEV1 50% of predicted. To adjust for Canadian pric-
ing, pertinent economic parameters were obtained from
the Ontario and Quebec Ministries of Health. Usual care
data were obtained from a Delphi panel composed of the
medical directors of the cystic fibrosis clinics. 
RESULTS: Pertinent pharmacoeconomic results reported
in days and 95% CI were as follows: In hospital: T 
5.2, P  8.2; Dif  3 (5.02 to 0.97). Home IV ther-
apy: T  5.9, P  10.1; Dif.  3.1 (6.25 to 1.03).
Home oral therapy: T  15.4, P  18.1; Dif  2.7
(6.52 to 1.07). The average savings in direct medical
costs that could be produced by the use of T during a 20-
week treatment period in Quebec and Ontario would
amount to $10,802 per patient. A maximal saving of
$22,735 would be obtained in Ontario children with
FEV1 50% of predicted. A minimal saving of $4869
would correspond to Quebec adults with FEV1 50% of
predicted. 
CONCLUSIONS: Substantial savings in direct medical
costs could be obtained by using inhaled T to decrease
the rate of recurrent pulmonary infections in patients
with cystic fibrosis.
ECONOMIC AND OUTCOMES ISSUES OF 
ARTHRITIC DISEASE
PAD1
EFFICACY OF AN INTERVENTION TO 
RATIONALIZE PRESCRIBING OF 
NON-STEROIDAL ANTI-INFLAMMATORY 
DRUGS (NSAIDs)
Elkharrat D, Chastang C, Le Corre A, Caulin C
Emergency Department, Hôpital Lariboisière, Paris, France
NSAIDs are considered minor drugs in that their clinical
benefit is limited to reduction of symptoms. Although
they may be responsible for about 25% of side effects,
some of them fatal, most NSAIDs are prescribed for con-
troversial indications. An intervention was prospectively
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undertaken to rationalize prescribing in an emergency de-
partment (ED). 
METHODS: The annual census of our ED is 50,000 pa-
tients, 40% of whom receive prescription drugs. Prescrip-
tions written by a total of 57 physicians were collected
during 5 days before (P1) a 45-day intervention, then 5
days immediately after (P2) and 12 days, 3 years later
(P3). The intervention was an educational program with
emphasis on contraindications and adverse effects. Con-
forming indications were either established (E) (mainly
rheumatological) or admitted (A) but controversial (trauma,
ENT). For the latter, NSAIDs may be withheld. Between
P1 and P2 all E&A indications were shown. Between P2
and P3, only the E indications were available. Prescribing
errors were the main endpoint. 
RESULTS: NSAIDs were prescribed for 37/434 patients
(8.5%), 42/414 (10%), and 12/583 (2%), respectively
(p  0.0001). Between P1 and P2, prescribing errors de-
creased from 19% to 14% (p  0.76). In P3, 1 was
found. Between P1 and P3, conforming prescriptions in-
creased from 81% to 92% (p  0.66): NSAIDs decreased
for trauma (50% to 8%; p  0.02) and increased for
rheumatology (19% to 42%; p  0.14). Duration of
treatment decreased from 8.0–4.0 days to 6.0–3.0 days
(p  0.07). 
CONCLUSIONS: Overall NSAIDs as well as incorrect
prescribing decreased after an intervention. However, 1)
“Soft indications” stimulated prescribing; 2) Its curbing
was obtained by a limited list between P2 and P3. This
approach may be applied to other controversial drugs.
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OPTIMIZATION OF AN HMO’s NSAID 
PORTFOLIO FOLLOWING THE INTRODUCTION 
OF CELECOXIB
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Significant opportunities for patient safety are potentially
achievable with the introduction of the cycloxygenase-2
(COX-2) inhibitors. Unfortunately, constrained health-
care budgets may limit their use. 
OBJECTIVE: To describe a NSAID therapeutic portfolio
that maximizes medical benefits, but does not increase
existing healthcare costs. 
METHODS: A meta-heuristic assisted optimization of a
typical HMO’s NSAID portfolio after the introduction of
celecoxib 200 mg QD was conducted using linear pro-
gramming techniques. Current NSAID  antiulcerant us-
age and the cost of managing NSAID related gastropathy
was derived from a large HMO. Background antiulcerant
usage was established from an equivalent non-NSAID ex-
posed arthritis population. The probabilities of NSAID
related gastrointestinal events were derived from clinical
trials and the literature. Decreased hospitalized gas-
trointestinal events without increasing the overall health
budget were defined as the optimization criteria. Antiul-
cerant usage was not allowed to decrease below the back-
ground rate.
RESULTS: Assuming an average risk of NSAID-induced
GI toxicity and 150 days/year of therapy, the average
cost/patient/year for NSAID therapy and related adverse
events would be $366. If celecoxib is introduced into the
healthcare system, 74% of patients could be switched to
the agent without increasing the overall budget, provided
that the remaining patients were distributed as follows:
13% generic ibuprofen; 9% generic NSAID  H2 block-
ers or prostaglandins; and 4% generic NSAID  PPI.
During a 1-year period, this distribution of agents would
result in 29 fewer physician visits and two less hospital-
ization per 1000 patients. 
CONCLUSIONS: These results indicate that by optimiz-
ing the distribution of NSAIDs utilized within a HMO, a
significant number of osteoarthritic patients can receive
safer COX-2 specific compounds such as celecoxib with-
out increasing the total budget.
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RESPONSIVENESS OF WOMAC IMPROVEMENT 
TO PATIENTS’ AND PHYSICIANS’ GLOBAL 
ASSESSMENT (PtGA & PhGA) OF IMPROVEMENT 
AMONG OSTEOARTHRITIS PATIENTS (OA)
Zhao SZ, Arguelles L, Burke TA, Osterhaus JT
G.D. Searle & Co., Skokie, IL, USA
OBJECTIVE: To provide a clinically meaningful inter-
pretation of improvements in WOMAC scores among
OA patients. 
METHODS: Data were obtained from three 12-week ran-
domized clinical trials among 3369 OA flare patients. The
Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC), PtGA & PhGA were administered at
baseline and week 12. WOMAC is a 24-item instrument
that contains three domains: pain, stiffness, and physical
functioning and a summary score. PtGA & PhGA were
measured on the following 5-point scale: very good, good,
fair, poor, or very poor. Change scores were computed by
subtracting patient’s baseline from week 12 follow-up
scores. Responsiveness was estimated as the mean change
score corresponding to each level of PtGA or PhGA im-
provement. 
RESULTS: At week 12, the number of patients experi-
encing improvements in PtGA and PhGA were: 1108 and
1158 for one-level, 708 and 745 for two-levels, and 368
and 311 for three or more levels. The average improve-
ment of WOMAC domain and total scores among pa-
tients experiencing one, two, or three or more levels of
PtGA improvement were 2.3, 4.4, 6.5 for pain, 1.0, 1.7,
2.5 for stiffness, 7.3, 13.9, 20.4 for physical functioning,
and 10.1, 18.7, 27.4 for total WOMAC score. A similar
responsiveness was found between average WOMAC
scores and PhGA improvement, which were 2.3, 4.4, 6.6
for pain, 1.0, 1.7, 2.5 for stiffness, 7.5, 13.6, 21.0 for
physical-functioning, and 10.3, 18.6, 27.9 for total
WOMAC score. 
